المؤلفون: Oscar Mammoliti (1923286), Koen Jansen (1822096), Sandy El Bkassiny (10740138), Adeline Palisse (10740135), Nicolas Triballeau (1400671), Denis Bucher (352807), Brigitte Allart (2944395), Alex Jaunet (1863439), Giovanni Tricarico (9941678), Maxim De Wachter (11494630), Christel Menet (9941675), Javier Blanc (1714399), Vatroslav Letfus (11494633), Renata Rupčić (2115004), Mario Šmehil (11494636), Tanja Poljak (11494639), Beatrice Coornaert (10740141), Kathleen Sonck (5898149), Inge Duys (10740144), Ludovic Waeckel (11494642), Lola Lecru (332155), Florence Marsais (11494645), Catherine Jagerschmidt (753692), Marielle Auberval (3989720), Philippe Pujuguet (11494648), Line Oste (1705675), Monica Borgonovi (4747311), Emanuelle Wakselman (1705648), Thierry Christophe (242276), Nicolas Houvenaghel (10740147), Mia Jans (4376776), Bertrand Heckmann (632958), Laurent Sanière (10740150), Reginald Brys (1705672)

مصطلحات موضوعية: Biochemistry, Medicine, Pharmacology, Biotechnology, Ecology, Cancer, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, potent phthalazone series, orally bioavailable phthalazone, increasing evidence suggests, chemical enablement strategy, progressive lung disease, s1p2 antagonists could, 6 , s1p2 antagonists, disease progression, vivo <, vitro <, s1p2 activity, three different, therapeutic setting, suboptimal pharmacokinetics, scaffold hopping, rapid exploration, position adjacent, mouse models, kg bid, homology model, good pharmacokinetics

Relation: https://figshare.com/articles/journal_contribution/Discovery_and_Optimization_of_Orally_Bioavailable_Phthalazone_and_Cinnolone_Carboxylic_Acid_Derivatives_as_S1P2_Antagonists_against_Fibrotic_Diseases/16692334

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c01066.s001

المؤلفون: Oscar Mammoliti (1923286), Koen Jansen (1822096), Sandy El Bkassiny (10740138), Adeline Palisse (10740135), Nicolas Triballeau (1400671), Denis Bucher (352807), Brigitte Allart (2944395), Alex Jaunet (1863439), Giovanni Tricarico (9941678), Maxim De Wachter (11494630), Christel Menet (9941675), Javier Blanc (1714399), Vatroslav Letfus (11494633), Renata Rupčić (2115004), Mario Šmehil (11494636), Tanja Poljak (11494639), Beatrice Coornaert (10740141), Kathleen Sonck (5898149), Inge Duys (10740144), Ludovic Waeckel (11494642), Lola Lecru (332155), Florence Marsais (11494645), Catherine Jagerschmidt (753692), Marielle Auberval (3989720), Philippe Pujuguet (11494648), Line Oste (1705675), Monica Borgonovi (4747311), Emanuelle Wakselman (1705648), Thierry Christophe (242276), Nicolas Houvenaghel (10740147), Mia Jans (4376776), Bertrand Heckmann (632958), Laurent Sanière (10740150), Reginald Brys (1705672)

مصطلحات موضوعية: Biochemistry, Medicine, Pharmacology, Biotechnology, Ecology, Cancer, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, potent phthalazone series, orally bioavailable phthalazone, increasing evidence suggests, chemical enablement strategy, progressive lung disease, s1p2 antagonists could, 6 , s1p2 antagonists, disease progression, vivo <, vitro <, s1p2 activity, three different, therapeutic setting, suboptimal pharmacokinetics, scaffold hopping, rapid exploration, position adjacent, mouse models, kg bid, homology model, good pharmacokinetics

Relation: https://figshare.com/articles/dataset/Discovery_and_Optimization_of_Orally_Bioavailable_Phthalazone_and_Cinnolone_Carboxylic_Acid_Derivatives_as_S1P2_Antagonists_against_Fibrotic_Diseases/16692340

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c01066.s002

المؤلفون: Oscar Mammoliti (1923286), Koen Jansen (1822096), Sandy El Bkassiny (10740138), Adeline Palisse (10740135), Nicolas Triballeau (1400671), Denis Bucher (352807), Brigitte Allart (2944395), Alex Jaunet (1863439), Giovanni Tricarico (9941678), Maxim De Wachter (11494630), Christel Menet (9941675), Javier Blanc (1714399), Vatroslav Letfus (11494633), Renata Rupčić (2115004), Mario Šmehil (11494636), Tanja Poljak (11494639), Beatrice Coornaert (10740141), Kathleen Sonck (5898149), Inge Duys (10740144), Ludovic Waeckel (11494642), Lola Lecru (332155), Florence Marsais (11494645), Catherine Jagerschmidt (753692), Marielle Auberval (3989720), Philippe Pujuguet (11494648), Line Oste (1705675), Monica Borgonovi (4747311), Emanuelle Wakselman (1705648), Thierry Christophe (242276), Nicolas Houvenaghel (10740147), Mia Jans (4376776), Bertrand Heckmann (632958), Laurent Sanière (10740150), Reginald Brys (1705672)

مصطلحات موضوعية: Biochemistry, Medicine, Pharmacology, Biotechnology, Ecology, Cancer, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, potent phthalazone series, orally bioavailable phthalazone, increasing evidence suggests, chemical enablement strategy, progressive lung disease, s1p2 antagonists could, 6 , s1p2 antagonists, disease progression, vivo <, vitro <, s1p2 activity, three different, therapeutic setting, suboptimal pharmacokinetics, scaffold hopping, rapid exploration, position adjacent, mouse models, kg bid, homology model, good pharmacokinetics

Relation: https://figshare.com/articles/dataset/Discovery_and_Optimization_of_Orally_Bioavailable_Phthalazone_and_Cinnolone_Carboxylic_Acid_Derivatives_as_S1P2_Antagonists_against_Fibrotic_Diseases/16692349

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c01066.s004

المؤلفون: Oscar Mammoliti (1923286), Koen Jansen (1822096), Sandy El Bkassiny (10740138), Adeline Palisse (10740135), Nicolas Triballeau (1400671), Denis Bucher (352807), Brigitte Allart (2944395), Alex Jaunet (1863439), Giovanni Tricarico (9941678), Maxim De Wachter (11494630), Christel Menet (9941675), Javier Blanc (1714399), Vatroslav Letfus (11494633), Renata Rupčić (2115004), Mario Šmehil (11494636), Tanja Poljak (11494639), Beatrice Coornaert (10740141), Kathleen Sonck (5898149), Inge Duys (10740144), Ludovic Waeckel (11494642), Lola Lecru (332155), Florence Marsais (11494645), Catherine Jagerschmidt (753692), Marielle Auberval (3989720), Philippe Pujuguet (11494648), Line Oste (1705675), Monica Borgonovi (4747311), Emanuelle Wakselman (1705648), Thierry Christophe (242276), Nicolas Houvenaghel (10740147), Mia Jans (4376776), Bertrand Heckmann (632958), Laurent Sanière (10740150), Reginald Brys (1705672)

مصطلحات موضوعية: Biochemistry, Medicine, Pharmacology, Biotechnology, Ecology, Cancer, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, potent phthalazone series, orally bioavailable phthalazone, increasing evidence suggests, chemical enablement strategy, progressive lung disease, s1p2 antagonists could, 6 , s1p2 antagonists, disease progression, vivo <, vitro <, s1p2 activity, three different, therapeutic setting, suboptimal pharmacokinetics, scaffold hopping, rapid exploration, position adjacent, mouse models, kg bid, homology model, good pharmacokinetics

Relation: https://figshare.com/articles/dataset/Discovery_and_Optimization_of_Orally_Bioavailable_Phthalazone_and_Cinnolone_Carboxylic_Acid_Derivatives_as_S1P2_Antagonists_against_Fibrotic_Diseases/16692343

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c01066.s003